Poon Christine A 的 Form 4 申報
Regeneron Pharmaceuticals, Inc.（REGN），2025/10/31 申報
- 申報編號
- 0001189014-25-000005
- 申報時間
- 2025/10/31
- 交易日
- 2025/10/29-10/30
- 申報延遲
- 2 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 8 筆非衍生性交易、2 筆衍生性交易。公開市場賣出合計 $425.3 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Poon Christine ACIK 0001189014 | 董事 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/10/29 | Common Stock | M行使選擇權取得 | +6,500 | $520.01 | +$3,380,065 | 8,852 | 直接 | |
| 2025/10/29 | Common Stock | S賣出處分 | −650 | $652.68F1 | −$424,242 | 8,202 | 直接 | |
| 2025/10/29 | Common Stock | S賣出處分 | −2,735 | $653.50F2 | −$1,787,322.5 | 5,467 | 直接 | |
| 2025/10/29 | Common Stock | S賣出處分 | −1,915 | $654.42F3 | −$1,253,214.3 | 3,552 | 直接 | |
| 2025/10/29 | Common Stock | S賣出處分 | −100 | $655.10F4 | −$65,510 | 3,452 | 直接 | |
| 2025/10/29 | Common Stock | S賣出處分 | −712 | $656.50F5 | −$467,428 | 2,740 | 直接 | |
| 2025/10/29 | Common Stock | S賣出處分 | −388 | $657.29F6 | −$255,028.52 | 2,352 | 直接 | |
| 2025/10/30 | Common Stock | M行使選擇權取得 | +2,712 | $520.01 | +$1,410,267.12 | 5,064 | 直接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/10/29 | Common Stock | M行使選擇權處分 | −6,500 | $0.00 | $0 | 2,712 | 直接 | |
| 2025/10/30 | Common Stock | M行使選擇權處分 | −2,712 | $0.00 | $0 | 0 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Represents volume-weighted average price of sales of 650 shares of Company stock on October 29, 2025 at prices ranging from $652.31 to $652.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F2
Represents volume-weighted average price of sales of 2,735 shares of Company stock on October 29, 2025 at prices ranging from $653.05 to $653.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F3
Represents volume-weighted average price of sales of 1,915 shares of Company stock on October 29, 2025 at prices ranging from $654.01 to $654.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F4
Represents volume-weighted average price of sales of 100 shares of Company stock on October 29, 2025 at prices ranging from $655.02 to $655.16. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F5
Represents volume-weighted average price of sales of 712 shares of Company stock on October 29, 2025 at prices ranging from $656.33 to $656.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F6
Represents volume-weighted average price of sales of 388 shares of Company stock on October 29, 2025 at prices ranging from $657.02 to $657.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。